Regenerative Medicine Advanced Therapy Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
HUMA | D | Humacyte, Inc. | 10.96 | |
PROK | D | ProKidney Corp. | 4.02 | |
LCTX | F | Lineage Cell Therapeutics, Inc. | -1.46 | |
INAB | F | IN8bio, Inc. | -1.21 |
Related Industries: Biotechnology
Related ETFs - A few ETFs which own one or more of the above listed Regenerative Medicine Advanced Therapy stocks.
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
BTEC | C | Principal Healthcare Innovators Index ETF | 0.16 | |
IWC | C | iShares Microcap ETF | 0.11 | |
XBI | C | SPDR S&P Biotech ETF | 0.08 | |
IBBQ | B | Invesco Nasdaq Biotechnology ETF | 0.06 | |
LABU | C | Direxion Daily S&P Biotech Bull 3X Shares | 0.05 |
Compare ETFs
Related Industries:
Biotechnology
- Regenerative Medicine Advanced Therapy
Regenerative Medicine Advanced Therapy (RMAT) is a designation given by the Food and Drug Administration to drug candidates intended to treat serious or life-threatening conditions under the 21st Century Cures Act. A RMAT designation allows for accelerated approval based surrogate or intermediate endpoints.RMAT goes beyond breakthrough therapy features by allowing for accelerated approval of drugs based on surrogate endpoints. A surrogate endpoint is a biomarker that substitutes for a direct endpoint, such as clinical benefit.
Recent Comments
- TraderMike on Bollinger Band Squeeze
- TraderMike on Bollinger Band Squeeze
- OpenCat584 on Bollinger Band Squeeze
- Dr_Duru on Expansion Breakout
- TraderMike on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
From the Blog
Featured Articles